R S Sperling
Overview
Explore the profile of R S Sperling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
1140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
DeTora L, Krupa D, Bolognese J, Sperling R, Ehrich E
J Rheumatol
. 2001 Nov;
28(11):2494-503.
PMID: 11708424
Objective: To evaluate the efficacy of rofecoxib (Vioxx) in subpopulations of patients with osteoarthritis (OA) identified by demographic or baseline disease characteristics, or varied OA involvement. Methods: Data were combined...
2.
Konstam M, Weir M, Reicin A, Shapiro D, Sperling R, Barr E, et al.
Circulation
. 2001 Nov;
104(19):2280-8.
PMID: 11696466
Background: In comparing aspirin, nonselective nonsteroidal antiinflammatory agents (NSAIDs), and cyclooxygenase (COX)-2 inhibitors, variation in platelet inhibitory effects exists that may be associated with differential risks of cardiovascular (CV) thrombotic...
3.
Truitt K, Sperling R, Ettinger Jr W, Greenwald M, DeTora L, Zeng Q, et al.
Aging (Milano)
. 2001 Jun;
13(2):112-21.
PMID: 11405384
This 6-week study was conducted to test the efficacy, safety, and tolerability of rofecoxib (a selective COX-2 inhibitor) compared to nabumetone (a non-selective NSAID) and placebo in osteoarthritis (OA) patients...
4.
Shapiro D, Sperling R, Mandelbrot L, Britto P, Cunningham B
Obstet Gynecol
. 1999 Nov;
94(6):897-908.
PMID: 10576173
Objective: To identify modifiable obstetric factors associated with the failure of zidovudine chemoprophylaxis to prevent perinatal human immunodeficiency virus type 1 (HIV-1) transmission. Methods: We analyzed data from Pediatric AIDS...
5.
Brambilla D, Reichelderfer P, Bremer J, Shapiro D, Hershow R, Katzenstein D, et al.
AIDS
. 1999 Nov;
13(16):2269-79.
PMID: 10563712
Objectives: To assess the specific contributions of assay variation and biological variation to the total variation of plasma HIV-1 RNA measured by the Roche Monitor assay and the extent to...
6.
Shapiro D, Sperling R, Coombs R
Lancet
. 1999 Jul;
354(9173):156; author reply 157-8.
PMID: 10408505
No abstract available.
7.
McSherry G, Shapiro D, Coombs R, McGrath N, Frenkel L, Britto P, et al.
J Pediatr
. 1999 Jun;
134(6):717-24.
PMID: 10356140
Objective: To describe the effect of zidovudine on human immunodeficiency virus type 1 (HIV-1) and on the course of disease in infants who became infected while they and their mothers...
8.
Hanson I, Antonelli T, Sperling R, Oleske J, Cooper E, Culnane M, et al.
J Acquir Immune Defic Syndr Hum Retrovirol
. 1999 May;
20(5):463-7.
PMID: 10225228
Zidovudine (ZDV) therapy during pregnancy and to the neonate reduced perinatal HIV transmission by nearly 70% in Pediatric AIDS Clinical Trials Group (PACTG) protocol 076. ZDV has been reported as...
9.
Sperling R, Shapiro D, McSherry G, Britto P, Cunningham B, Culnane M, et al.
AIDS
. 1998 Oct;
12(14):1805-13.
PMID: 9792381
Objective: To determine the safety of the zidovudine (ZDV) regimen utilized in the Pediatric AIDS Clinical Trial Group (ACTG) 076 study. Design: ACTG 076 was a randomized, double-blind, placebo-controlled trial...
10.
Mirochnick M, Fenton T, Gagnier P, Pav J, Gwynne M, Siminski S, et al.
J Infect Dis
. 1998 Aug;
178(2):368-74.
PMID: 9697716
The safety, toxicity, and pharmacokinetics of intrapartum and early newborn nevirapine were evaluated in 17 human immunodeficiency virus type 1-infected women in labor and their newborns. No adverse effects of...